D-penicillamine	d-penicillamine	S_chemicals	O
in	in	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
localized	localized	O	B_disease
scleroderma	scleroderma	O	I_disease
.	.	O	O

Localized	localized	O	B_disease
scleroderma	scleroderma	O	I_disease
has	has	O	O
no	no	O	O
recognized	recognized	O	O
internal	internal	O	O
organ	organ	O	O
involvement	involvement	O	O
but	but	O	O
may	may	O	O
be	be	O	O
disfiguring	disfiguring	O	O
and	and	O	O
disabling	disabling	O	O
when	when	O	O
the	the	O	O
cutaneous	cutaneous	O	O
lesions	lesions	O	O
are	are	O	O
extensive	extensive	O	O
or	or	O	O
affect	affect	O	O
children	children	O	O
.	.	O	O

There	there	O	O
is	is	O	O
no	no	O	O
accepted	accepted	O	O
or	or	O	O
proven	proven	O	O
treatment	treatment	O	O
for	for	O	O
localized	localized	O	B_disease
scleroderma	scleroderma	O	I_disease
.	.	O	O

Case	case	O	O
reports	reports	O	O
of	of	O	O
11	11	O	O
patients	patients	O	O
with	with	O	O
severe	severe	O	O
,	,	O	O
extensive	extensive	O	O
localized	localized	O	B_disease
scleroderma	scleroderma	O	I_disease
who	who	O	O
were	were	O	O
treated	treated	O	O
with	with	O	O
D-penicillamine	d-penicillamine	S_chemicals	O
are	are	O	O
summarized	summarized	O	O
in	in	O	O
this	this	O	O
article	article	O	O
.	.	O	O

This	this	O	O
drug	drug	S_chemicals	O
was	was	O	O
judged	judged	O	O
to	to	O	O
have	have	O	O
a	a	O	O
favorable	favorable	O	O
effect	effect	O	O
on	on	O	O
the	the	O	O
disease	disease	O	S_disease
course	course	O	O
in	in	O	O
7	7	O	O
(	(	O	O
64	64	O	O
%	%	O	O
)	)	O	O
of	of	O	O
11	11	O	O
patients	patients	O	O
.	.	O	O

Improvement	improvement	O	O
began	began	O	O
within	within	O	O
3	3	O	O
to	to	O	O
6	6	O	O
months	months	O	O
and	and	O	O
consisted	consisted	O	O
of	of	O	O
cessation	cessation	O	O
of	of	O	O
active	active	O	O
cutaneous	cutaneous	O	O
lesions	lesions	O	O
in	in	O	O
all	all	O	O
7	7	O	O
patients	patients	O	O
,	,	O	O
skin	skin	O	O
softening	softening	O	O
in	in	O	O
5	5	O	O
,	,	O	O
and	and	O	O
more	more	O	O
normal	normal	O	O
growth	growth	O	O
of	of	O	O
the	the	O	O
affected	affected	O	O
limb	limb	O	O
in	in	O	O
2	2	O	O
of	of	O	O
3	3	O	O
children	children	O	O
.	.	O	O

Joint	joint	O	O
stiffness	stiffness	O	O
and	and	O	O
contractures	contractures	O	S_disease
also	also	O	O
improved	improved	O	O
.	.	O	O

The	the	O	O
dose	dose	O	O
of	of	O	O
D-penicillamine	d-penicillamine	S_chemicals	O
associated	associated	O	O
with	with	O	O
a	a	O	O
favorable	favorable	O	O
response	response	O	O
was	was	O	O
as	as	O	O
low	low	O	O
as	as	O	O
2	2	O	O
to	to	O	O
5	5	O	O
mg/kg	mg/kg	O	O
per	per	O	O
day	day	O	O
given	given	O	O
over	over	O	O
a	a	O	O
period	period	O	O
ranging	ranging	O	O
from	from	O	O
15	15	O	O
to	to	O	O
53	53	O	O
months	months	O	O
.	.	O	O

D-Penicillamine	d-penicillamine	S_chemicals	O
caused	caused	O	O
nephrotic	nephrotic	O	B_disease
syndrome	syndrome	O	S_disease
in	in	O	O
1	1	O	O
patient	patient	O	O
and	and	O	O
milder	milder	O	O
reversible	reversible	O	O
proteinuria	proteinuria	O	S_disease
in	in	O	O
3	3	O	O
other	other	O	O
patients	patients	O	O
;	;	O	O
none	none	O	O
developed	developed	O	O
renal	renal	O	B_disease
insufficiency	insufficiency	O	I_disease
.	.	O	O

These	these	O	O
data	data	O	O
suggest	suggest	O	O
that	that	O	O
D-penicillamine	d-penicillamine	S_chemicals	O
may	may	O	O
be	be	O	O
effective	effective	O	O
in	in	O	O
severe	severe	O	O
cases	cases	O	O
of	of	O	O
localized	localized	O	B_disease
scleroderma	scleroderma	O	I_disease
.	.	O	O

